Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk

ID#: NCT03036254

Age: 65 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: October 08, 2017

End Date: November 30, 2021

Contact Information:
Michal Schnaider-Beeri, PhD
212-659-8807
Ramit Ravona, PhD
972-3-5303825
Summary: An urgent need exists to identify effective interventions to arrest or reverse dementia and cognitive loss at its earliest stages. The proposed pilot randomized clinical trial will investigate the short and long-term effects of hyperbaric oxygen therapy on cognitive functioning, cerebral blood flow, and glucose uptake in diabetic elderly with mild cognitive impairment. and provide the basis for a large-scale multi-center study of hyperbaric oxygen therapy effects on cognition in diabetes. The potential to preserve, or even enhance, cognition in elderly at high risk of cognitive decline and dementia has major implications for the affected individuals and their support systems that bear the social and financial burdens of long-term caregiving.
Eligibility:

Inclusion Criteria:

- Diagnosis of T2D

- Diagnosis of MCI

- > the age of 65

- Hebrew fluency

- An informant

Exclusion Criteria:

- Brain disease that affects cognition (e.g. Parkinson's disease, schizophrenia).

- Stroke

- Epilepsy

- Chest pathology incompatible with HBOT

- Inner ear disease

- Claustrophobia

- Cholinesterase inhibitors

- Subjects with an indication for HBOT

- Counter-indication for MRI or PET

- Individuals with severe cataracts must have cataract operations before enrolling in the study